Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

被引：0
|
作者：
Dalal, Rahul S. [1 ]
Clarke, Lindsay M. [1 ]
Carlin, Alex [1 ]
Cabral, Heidy [1 ]
Allegretti, Jessica R. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
来源：
INFLAMMATORY BOWEL DISEASES | 2024年
关键词：
ulcerative colitis; inflammatory bowel disease; biologics; bio-na & iuml; ve; INFLAMMATORY-BOWEL-DISEASE;
D O I：
10.1093/ibd/izae215
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-na & iuml;ve patients with ulcerative proctitis.
引用
收藏
页码：1174 / 1177
页数：4
相关论文
共 50 条
  • [41] Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
    Pudipeddi, Aviv
    Ko, Yanna
    Paramsothy, Sudarshan
    Leong, Rupert W.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [42] Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance
    Saeki, Hidehisa
    Fujita, Hiroyuki
    Suzuki, Katsuhisa
    Arima, Kazuhiko
    JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2023, 6 (03) : 78 - 87
  • [43] Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
    Plevris, N.
    Chuah, C. S.
    Allen, R. M.
    Arnott, I. D.
    Brennan, P. N.
    Chaudhary, S.
    Churchhouse, A. M. D.
    Din, S.
    Donoghue, E.
    Gaya, D. R.
    Groome, M.
    Jafferbhoy, H. M.
    Jenkinson, P. W.
    Lam, W. L.
    Lyons, M.
    Macdonald, J. C.
    MacMaster, M.
    Mowat, C.
    Naismith, G. D.
    Potts, L. F.
    Saffouri, E.
    Seenan, J. P.
    Sengupta, A.
    Shasi, P.
    Sutherland, D. I.
    Todd, J. A.
    Veryan, J.
    Watson, A. J. M.
    Watts, D. A.
    Jones, G. R.
    Lees, C. W.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (09) : 1111 - 1120
  • [44] Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study
    Farkas, Bernadett
    Bessissow, Talat
    Limdi, Jimmy K.
    Sethi-Arora, Karishma
    Kagramanova, Anna
    Knyazev, Oleg
    Bezzio, Cristina
    Armuzzi, Alessandro
    Lukas, Milan
    Michalopoulos, George
    Chaskova, Elena
    Savarino, Edoardo Vincenzo
    Castiglione, Fabiana
    Rispo, Antonio
    Schafer, Eszter
    Saibeni, Simone
    Filip, Rafal
    Attauabi, Mohamed
    Fousekis, Fotios S.
    Bacsur, Peter
    Resal, Tamas
    Balint, Anita
    Ivany, Emese
    Szepes, Zoltan
    Bosze, Zsofia
    Fabian, Anna
    Bor, Renata
    Farkas, Klaudia
    Lakatos, Peter L.
    Molnar, Tamas
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (24)
  • [45] Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases
    Attauabi, Mohamed
    Hoglund, Camilla
    Fassov, Janne
    Pedersen, Kenneth Bo
    Hansen, Heidi Bansholm
    Wildt, Signe
    Jensen, Michael Dam
    Neumann, Anders
    Lind, Cecilie
    Jacobsen, Henrik Albaek
    Popa, Ana-Maria
    Kjeldsen, Jens
    Pedersen, Natalia
    Molazahi, Akbar
    Haderslev, Kent
    Aalykke, Claus
    Knudsen, Torben
    Cebula, Wojciech
    Munkholm, Pia
    Bendtsen, Flemming
    Seidelin, Jakob Benedict
    Burisch, Johan
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2021, 56 (09) : 1040 - 1048
  • [46] Physical Activity in Adults with Severe Asthma On-Treatment with Biological Therapies: A 1-Year Retrospective Analysis of Real-World Data
    Caroline Reilly
    Antonios Stavropoulos-Kalinoglou
    Daniel Peckham
    Ian J. Clifton
    Oliver J. Price
    Pulmonary Therapy, 2025, 11 (2) : 307 - 313
  • [47] Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience
    Cussac, Cecile
    Riviere, Pauline
    Altwegg, Romain
    Caillo, Ludovic
    Poullenot, Florian
    Laharie, David
    Gilletta, Cyrielle
    Le Cosquer, Guillaume
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, : 1692 - 1696
  • [48] Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Systematic Review and Meta-Analysis of Observational Studies
    Rubin de Celix, Cristina
    Chaparro, Maria
    Gisbert, Javier P.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (14)
  • [49] Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
    Shimizu, Hiromichi
    Aonuma, Yuko
    Hibiya, Shuji
    Kawamoto, Ami
    Takenaka, Kento
    Fujii, Toshimitsu
    Saito, Eiko
    Nagahori, Masakazu
    Ohtsuka, Kazuo
    Okamoto, Ryuichi
    INTESTINAL RESEARCH, 2024, 22 (03) : 369 - 377
  • [50] Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study
    Hisamatsu, Tadakazu
    Suzuki, Yasuo
    Kobayashi, Mariko
    Hagiwara, Takashi
    Kawaberi, Takeshi
    Ogata, Haruhiko
    Matsui, Toshiyuki
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2021, 19 (04) : 408 - 418
12345